Requires health insurance and Medicaid coverage for testing and treatments to slow progression of Alzheimer's disease and related disorders.

Summary

The bill mandates that all health insurance policies and Medicaid plans in New Jersey must pay for medically necessary diagnostic testing and FDA‑approved drugs that slow Alzheimer’s disease and related disorders. Coverage must be provided at the same level as any other condition and cannot be limited by step‑therapy requirements. It applies to a wide range of insurance contracts, including individual, group, and corporate policies.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Topics

Share